CorMedix Inc. (CRMD)
CorMedix Statistics
Share Statistics
CorMedix has 65.18M shares outstanding. The number of shares has increased by 10.4% in one year.
| Shares Outstanding | 65.18M |
| Shares Change (YoY) | 10.4% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 39.02% |
| Shares Floating | 59.59M |
| Failed to Deliver (FTD) Shares | 1.21K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 8.26M, so 12.67% of the outstanding shares have been sold short.
| Short Interest | 8.26M |
| Short % of Shares Out | 12.67% |
| Short % of Float | 12.68% |
| Short Ratio (days to cover) | 5.42 |
Valuation Ratios
The PE ratio is -26.6 and the forward PE ratio is 6.85. CorMedix's PEG ratio is 0.4.
| PE Ratio | -26.6 |
| Forward PE | 6.85 |
| PS Ratio | 10.97 |
| Forward PS | 2 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0.4 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CorMedix.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.
| Current Ratio | 3.39 |
| Quick Ratio | 3.39 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | 0 |
| Interest Coverage | -614.1 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $679.25K |
| Profits Per Employee | $-280.16K |
| Employee Count | 64 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | -1.39M |
| Effective Tax Rate | 7.22% |
Stock Price Statistics
The stock price has increased by 79.52% in the last 52 weeks. The beta is 1.57, so CorMedix's price volatility has been higher than the market average.
| Beta | 1.57 |
| 52-Week Price Change | 79.52% |
| 50-Day Moving Average | 8.84 |
| 200-Day Moving Average | 8.65 |
| Relative Strength Index (RSI) | 67.37 |
| Average Volume (20 Days) | 1.41M |
Income Statement
In the last 12 months, CorMedix had revenue of 43.47M and earned -17.93M in profits. Earnings per share was -0.3.
| Revenue | 43.47M |
| Gross Profit | 40.28M |
| Operating Income | -22.36M |
| Net Income | -17.93M |
| EBITDA | -18.98M |
| EBIT | -19.29M |
| Earnings Per Share (EPS) | -0.3 |
Balance Sheet
The company has 40.65M in cash and 517.01K in debt, giving a net cash position of 40.13M.
| Cash & Cash Equivalents | 40.65M |
| Total Debt | 517.01K |
| Net Cash | 40.13M |
| Retained Earnings | -339.63B |
| Total Assets | 118.85M |
| Working Capital | 17.95M |
Cash Flow
In the last 12 months, operating cash flow was -50.61M and capital expenditures 0, giving a free cash flow of -50.61B.
| Operating Cash Flow | -50.61M |
| Capital Expenditures | 0 |
| Free Cash Flow | -50.61B |
| FCF Per Share | -859.75 |
Margins
Gross margin is 92.66%, with operating and profit margins of -51.43% and -41.24%.
| Gross Margin | 92.66% |
| Operating Margin | -51.43% |
| Pretax Margin | -44.45% |
| Profit Margin | -41.24% |
| EBITDA Margin | -43.66% |
| EBIT Margin | -51.43% |
| FCF Margin | -116430.01% |
Dividends & Yields
CRMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRMD is $14, which is 45.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 45.2% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 26, 2019. It was a backward split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 6.37 |
| Piotroski F-Score | 2 |